AstraZeneca and Galderma to collaborate
Sign five-year deal to develop treatments for dermatological diseases
AstraZeneca has entered into a five-year r&d deal to develop new treatments for skin conditions including psoriasis, acne and atopic dermatitis with Galderma Pharma of Switzerland.
Under the terms of the agreement, Galderma will have exclusive access to AstraZeneca compounds. Initial targets for collaboration will be from disease areas including oncology, inflammation and central nervous system, which will be interrogated based on translational science and pre-clinical testing to determine those that will be progressed. Financial terms were not disclosed.
Alain Jacot, vice president and chief scientific officer of Galderma, said the collaboration would complement its internal r&d efforts and ‘significantly enhance our ability to make important new discoveries that have the potential to treat serious dermatologic disorders’.
Clive Morris, head of New Opportunities Innovative Medicines Unit at AstraZeneca, said: ‘Partnering with Galderma, a world leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area.’
